CTL019 and other undisclosed CART products; over $100 million revenue potential over three years including $10 million upfront payment
The Group's priority in-house product development programmes continue to be prepared for clinical studies whilst discussions continue with potential partners
provides the Group with the financial flexibility to progress our key in-house programmes whilst continuing discussions with suitable collaborators
Next generation bioprocessing
The Group has recently developed a step-change in lentiviral vector production technology, moving from the use of labour intensive, manual, open processing in cell factories to next generation processing in single-use bioreactors. This new 200 litre process allows for larger scale production in closed single use systems, and has the potential to significantly increase capacity and efficiency. This increased efficiency will result in delivery of vector at lower cost of goods, which is important to support product commercialisation. The greater vector volumes that this process is capable of making also has the effect of unlocking indications that require large doses, such as muscle, liver and lung diseases. The Group has already successfully run the process at commercial scale.
technology companies Stratophase and Synthace, to further develop Oxford BioMedica's next generation suspension bioprocessing system. The two-year £2 million collaboration is partially funded by a grant from the UK's innovation agency, Innovate UK. During the collaboration, the partners will apply novel technologies to dynamically control bioreactors in real time and execute workflows to optimise operations and increase productivity.
Consequently, the TRiP system offers significant licensing opportunities for the Group as demand for vectors increases with the introduction of gene and cell therapy products.
OXB-102 (for Parkinson's disease), OXB-202 (for corneal graft rejection) and OXB-302 (for cancer)
OXB-102 (for Parkinson's disease)prepare the clinical study centres in Cambridge, London and Paris for initiation of the study. As a result, treatment of patients could begin early in 2018. In parallel a variety of potential financial partnership arrangements are being explored for each of the priority programmes. The Board is determined to ensure that the Group, and therefore shareholders, retains an appropriate share in the upside potential of these programmes. As such, the Group will continue to invest modestly in the programmes to maintain their momentum and to continue to enhance their value.
This has attracted additional interest from a range of potential partners and, as a result, the Group is conducting feasibility studies and discussions with a number of companies. The Group anticipates establishing further relationships over the next twelve months.
The Group intends to expand its portfolio of collaborations, and to attract third-party investment to accelerate the clinical development of its wholly-owned proprietary products.
AI
